Greenland Mines Ltd (NASDAQ: GRML) has announced a series of corporate milestones as it transitions into a focused rare earths and critical minerals company. The company plans to spin off its biotechnology division in the fourth quarter of 2026, a move that will allow it to concentrate on its mining assets, particularly the Sarfartoq rare earths project in Greenland.
Nasdaq has formally approved the company's application relating to its March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements. This approval is a significant step for the company, as it ensures continued listing on the exchange and provides clarity for investors.
The company also completed its acquisition of the Sarfartoq project on Sept. 1, following approval by the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. These figures highlight the economic potential of the project.
Greenland Mines said planned annual neodymium-praseodymium (NdPr) oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project's nine scheduled operating years. This underscores the strategic importance of the project in diversifying the global supply chain for rare earth elements, which are critical for electric vehicles, wind turbines, and other clean energy technologies.
In addition to the corporate restructuring, Greenland Mines is reshaping its board. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and capital markets veteran Jason Hawkins is joining as Greenland Mines advances Sarfartoq and its Skaergaard palladium-gold-platinum project. This change in board composition brings fresh expertise to guide the company through its next phase of growth.
The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
These developments come at a time when global demand for critical minerals is surging, driven by the transition to clean energy and the need to reduce dependence on China for rare earth elements. Greenland Mines' focus on NdPr is particularly timely, as these elements are essential for high-strength magnets used in many modern technologies.
The spin-off of the biotech division, which includes Klotho's KLTO-202 primary indication for ALS, will allow Greenland Mines to unlock value in its mining operations while providing its biotech shareholders with a pure-play investment opportunity. The company's ability to execute on its strategic plan will be closely watched by investors and industry observers alike.
For more information about Greenland Mines and its latest updates, visit the company's newsroom at https://ibn.fm/GRML.
